Overview

This trial is active, not recruiting.

Condition keratoconus
Treatments topography-based cxl (kxl2), conventional pulsed cxl (pcxl), riboflavin, avedro kxl ii
Phase phase 2
Sponsor Umeå University
Start date March 2014
End date October 2019
Trial size 50 participants
Trial identifier NCT02514200, KXL2

Summary

The purpose of this study is to determine whether individualized, topography-based corneal crosslinking for keratoconus can improve the optical outcomes of the treatment.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
Individualized pulsed topography-based corneal crosslinking; 1 second on, 1 second off; 7.2J/cm2 - 15.0J/cm2; arcuate treatment zone. The Avedro KXL II™ System is used for the crosslinking after epithelial debridement in topical anesthesia and application of topical riboflavin every 3 minutes for 10 minutes.
topography-based cxl (kxl2)
The keratoconus cornea is treated with epithelial debridement in local anesthesia, and then soaked in Riboflavin by repeated topical application every 3 minutes during 10 minutes. The cornea is then irradiated with pulsed ultraviolet light (1s on/1s off) in a topography-based arcuate shape with the Avedro KXL2® with an energy from 7.2-15.0 J/cm2 depending on the severity of the keratoconus.
riboflavin
Riboflavin is added topically immediately before the treatment every 3 minutes during 10 minutes in the eye to be treated
avedro kxl ii
The KXL II™ System crosslinking device from Avedro, Inc. is used for ultraviolet irradiation of the cornea after riboflavin application in both treatment arms.
(Active Comparator)
Conventional pulsed corneal crosslinking; 1 second on, 1 second off; 5.4 J/cm2; 8 mm central treatment zone. The Avedro KXL II™ System is used for the crosslinking after epithelial debridement in topical anesthesia and application of topical riboflavin every 3 minutes for 10 minutes.
conventional pulsed cxl (pcxl)
The keratoconus cornea is treated with epithelial debridement in local anesthesia, and then soaked in Riboflavin by repeated topical application every 3 minutes during 10 minutes. The cornea is then irradiated with pulsed ultraviolet light (1s on/1s off) in a central round 8mm zone with the Avedro KXL2® with an energy of 5.4 J/cm2.
riboflavin
Riboflavin is added topically immediately before the treatment every 3 minutes during 10 minutes in the eye to be treated
avedro kxl ii
The KXL II™ System crosslinking device from Avedro, Inc. is used for ultraviolet irradiation of the cornea after riboflavin application in both treatment arms.

Primary Outcomes

Measure
Change from baseline in refraction
time frame: 1, 3, 6 and 12 months after the treatment

Secondary Outcomes

Measure
Change from baseline in ETDRS LogMAR visual acuity
time frame: 1, 3, 6 and 12 months after the treatment
Change from baseline in corneal densitometry
time frame: 1, 3, 6 and 12 months after the treatment
Change from baseline in corneal biomechanical stability measured with GAT
time frame: 1, 3, 6 and 12 months after the treatment
Change from baseline in corneal biomechanical stability measured with CorVis®
time frame: 1, 3, 6 and 12 months after the treatment
Change from baseline in corneal endothelial morphometry
time frame: 1, 3, 6 and 12 months after the treatment

Eligibility Criteria

Male or female participants at least 12 years old.

Inclusion Criteria: 1. Patients planned for corneal crosslinking. 2. Uni-or bilateral keratoconus diagnosis based on the Amsler‐Krumeich grading and the "Total Deviation" keratoconus quantification value from the "Belin‐Ambrosio enhanced ectasia" measurements of the Pentacam HR® Scheimpflug camera, and an altered red reflex and/or an irregular cornea seen as distortion of the keratometric mires. 3. Progression of the keratoconus in the eye in question, documented with Scheimpflug photography using the Oculus Pentacam HR® Scheimpflug camera and/or repeated subjective refraction and keratometry. 4. Minimum corneal thickness of 400 μm at the thinnest point after epithelial removal. 5. ≥12 years of age 6. No ocular abnormalities except keratoconus 7. No previous ocular surgery 8. No cognitive insufficiency interfering with the informed consent. Exclusion Criteria: 1. Age under 12 2. Any corneal abnormalities except keratoconus 3. Previous ocular surgery 4. Cognitive insufficiency

Additional Information

Official title Treatment of Keratoconus With Advanced Corneal Crosslinking-II
Description The study is designed as a prospective, open label, randomized controlled trial involving patients aged 12 years or older of both genders with uni‐ or bilateral keratoconus planned for routine corneal crosslinking (CXL) at the Department of Clinical Sciences / Ophthalmology, Umeå University Hospital, Umeå, Sweden. The study involves 25+25 eyes with keratoconus, which are randomized to receive either conventional pulsed crosslinking with a uniform, universal 8 mm treatment pattern of 5.4 J/cm2 (pCXL; n=25), or a modified treatment ‐ individualized topography-based corneal crosslinking (KXL2; n=25). In the latter treatment zone has an individualized arcuate shape and spares a 2 mm central optical zone. The size of the treatment zone is based on Pentacam HR® corneal tomography, and is determined by the transition zone where the corneal curvature drops off by ≥2D. The energy distribution is based on the maximum corneal steepness (Kmax) value retrieved from the Pentacam HR® tomography: ≤47.0D - 7.2 J/cm2; 47.1-52.0D - 10 J/cm2; ≥52.1D - 15 J/cm2. Thus, the thin protruding areas of the cornea are crosslinked, whereas the parts with a more normal shape are not. The aim is to potentially improve the optical outcome after the treatment. Patients are randomized to either of the two treatment arms utilizing a computer list of unique random numbers between 1 and 50; an even number will be treated with KXL2 and an uneven number with pCXL. Bilateral inclusion is allowed, and the second eye to be treated will be assigned to the other group, i.e. eye number two will not get the same treatment as eye number 1. All patients are informed about the procedures and provide oral and written consent before inclusion in the study. At baseline, before treatment, each eye is evaluated with autorefractometer measurement (Oculus Parc-1®), uncorrected and best spectacle‐corrected LogMAR visual acuity, Oculus Pentacam HR® Scheimpflug photography, Oculus CorVis® high-speed Scheimpflug photography, corneal endothelial photography with a specular microscope camera, Goldmann applanation tonometry and biomicroscopy. For the Pentacam HR® rotating Scheimpflug camera, each eye is photographed using the "25 pictures" program under standardized, mesopic light conditions. Multiple variables will be analyzed, and individual photographs also will be analyzed manually for light backscatter and for the occurrence of a demarcation line, by a masked observer. The corneal biomechanical characteristics are assessed with data from the Oculus CorVis®, and corneal endothelial morphometry, including endothelial cell density is assessed manually and automatically from specular microscopy photographs taken with the Topcon SP-2000 endothelial camera. All investigations are repeated at 1 month, 3 months, 6 months and 12 months after the treatment.
Trial information was received from ClinicalTrials.gov and was last updated in October 2016.
Information provided to ClinicalTrials.gov by Umeå University.